{
    "nctId": "NCT05814224",
    "briefTitle": "Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA",
    "officialTitle": "Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA",
    "overallStatus": "RECRUITING",
    "conditions": "Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases, Antineoplastic Agents, Aromatase Inhibitors, ESR1 Gene Mutation",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 164,
    "primaryOutcomeMeasure": "Liquid-biopsy in monitoring treatment response in luminal breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease.\n* ER positive tumor \u2265 1%\n* HER2 negative breast cancer by FISH or IHC (IHC 0,1+, 2+ and/or FISH HER2: CEP17 ratio \\< 2.0)\n* Females, 18 years of age or older\n* Candidate to first-line endocrine therapy (LH-RH analogue for premenopausal women is allowed)\n* Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.\n\nExclusion Criteria:\n\n* Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.\n* Prior endocrine therapy for metastatic disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}